NCT06033742View on ClinicalTrials.gov

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

November 13, 2021

Primary Completion Date

March 24, 2023

Study Completion Date

March 24, 2023

Conditions
Psoriasis
Interventions
DRUG

HS-10374 tablets

Single or multiple dosing of HS-10374 orally in a fasting state

DRUG

HS-10374-matched placebo tablets

Single or multiple dosing of HS-10374-matched placebo orally in a fasting state

Trial Locations (1)

200040

Huashan Hospital Affiliated to Fudan University, Shanghai

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY